Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Yonsei University College of Medicine, Seoul, Korea.

Survival: monthsCountry:Korea
Toxiciy Grade:3City/State/Province:Seoul
Treatments:ChemotherapyHospital:Yonsei University College of Medicine
Drugs:Journal:Link
Date:Jun 2007

Description:

Patients: This phase II study involved 21 patients with stage IIIB/IV recurrent or metastatic non-small-cell lung cancer. All had received prior chemotherapy including gefitinib. The median age was 56 years old. Eleven of the patients had never smoked.

Treatment: All patients were treated with the chemotherapy drug erlotinib.

Toxicity: Grade 3 skin rash and vomiting were reported in one and two patients, respectively. The most common adverse event was grade 1/2 skin rash.

Results: The median overall survival was 158 days (5.2 months).

Correspondence: Dr. Joo Hang Kim



Back